Baystate Wealth Management’s Myriad Genetics MYGN Stock Holding History

Baystate Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1	Closed	–	–	732
2020 Q3	$0	Buy	+1	New	+$13	﹤0.01%	707

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baystate Wealth Management's MYGN Position: Q4 2020 in Review

Baystate Wealth Management sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 1 share.

Baystate Wealth Management first reported a position in MYGN in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.

Baystate Wealth Management reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
Baystate Wealth Management sold 1 Myriad Genetics share in Q4 2020.
Baystate Wealth Management first reported a position in Myriad Genetics in Q3 2020 and held it in 1 quarter.
Baystate Wealth Management's Myriad Genetics position peaked at $0 in Q3 2020.
187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.

Based on Baystate Wealth Management's 13F filing for Q4 2020, filed 15 Jan 2021.